The highly anticipated annual biotechnology event — BIO Asia–Taiwan 2025 Exhibition— will be held from July 24 to 27 at the Taipei Nangang Exhibition Center. Amaran Biotech is proud to debut its new brand identity and vision, showcasing major advancements in aseptic filling line, adjuvant technologies, and global partnerships. Visit us at Booth M726, located in the CDMO zone — we warmly welcome industry partners for dialogue and collaboration.
As a one-stop Contract Development and Manufacturing Organization (CDMO), Amaran Biotech provides integrated solutions encompassing vaccine adjuvant AB-801 (QS-21), drug substance manufacturing, and aseptic filling of drug products. With the implementation of a fully automated robotic aseptic filling line, the company has continued to expand both technological depth and market presence. In 2024, Amaran Biotech achieved nearly 30% revenue growth, underscoring the trust placed in its high-quality manufacturing services.
Exhibition Highlights:
- Pre-filled Syringe (PFS) Capability Built and Validated: Amaran Biotech has completed tooling development and validation for PFS on its aseptic filling line, supporting clients aiming to meet stringent regulatory requirements in the U.S. market. This milestone signifies the company’s readiness to support commercialization and international CDMO partnerships for advanced injectable products.
- Partnerships with Nippon Fine Chemical and Zillion Fine Chemicals to Expand Nanomedicine Capabilities: Collaborating with Japanese pharma leaders Nippon Fine Chemical and Zillion Fine Chemicals, Amaran Biotech is expanding its footprint in liposomes and lipid nanoparticles formulations. This tripartite alliance highlights a shared vision and robust capabilities in advanced drug delivery development.
- Dual Recognition from IMAPAC: Technical and Quality Excellence: Amaran Biotech was honored with two prestigious IMAPAC awards this year
．Bioprocessing Excellence in Taiwan (Asia-Pacific Biopharma Excellence Awards 2025)
．Best CDMO in Automated Aseptic Filling (Taiwan Biopharma Excellence Awards 2025)
These accolades underscore the company’s innovation in adjuvant process development and automation integration — achievements that have garnered growing recognition in the global biopharma market.
This year also marks the official launch of Amaran Biotech’s new brand identity, expressing the company’s core spirit: “Formulating the Future, Producing Success.” This new brand reflects Amaran’s dedication to professional manufacturing, innovative technologies, and global vision. By upgrading its corporate image and increasing global visibility, the company is poised for its next phase of growth. Dr. Tessie Che, Chairperson and General Manager, stated: “Through technological innovation and strategic partnerships, we aim to accelerate product development and global expansion for our clients. With our renewed brand spirit at the core, Amaran Biotech will continue strengthening its leadership in the high-value biopharmaceutical CDMO sector.”